PsychiatryNews.net

Psychiatry Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

BOLDER II study confirms therapeutic potential of Seroquel in major depressive episodes associated with bipolar disorder


Results from the BOLDER II ( BipOLar DepRession ) study have underlined the potential for Seroquel ( Quetiapine ) in the treatment of patients with major depressive episodes associated with bipolar disorder.

In BOLDER II, Seroquel 300mg and 600mg doses achieved a statistically significant reduction in levels of bipolar depression compared with placebo ( p


Indietro